Angiogenic Gene Therapy

Ad5FGF-4 shows improvement in myocardial perfusion in phase II study

Published in Gene Therapy Weekly, April 11th, 2002

Schering AG (SHR; FSE: SCH), its U.S. affiliate Berlex Laboratories, Inc., and Collateral Therapeutics, Inc., (CLTX), announced results from a phase II double-blind, placebo-controlled study demonstrating that their product candidate Ad5FGF-4 showed improvement in myocardial perfusion (blood flow to the heart) in patients with moderate-to-severe exertional angina.

Ad5FGF-4 is an angiogenic gene therapy product that is being developed for the treatment of patients with stable exertional angina due to coronary artery disease.

"We are encouraged by these results and will vigorously pursue our clinical development program for the product, that includes...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-04-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry